Show simple item record

dc.contributor.authorShroff, Rachna T
dc.contributor.authorKennedy, Erin B
dc.contributor.authorBachini, Melinda
dc.contributor.authorBekaii-Saab, Tanios
dc.contributor.authorCrane, Christopher
dc.contributor.authorEdeline, Julien
dc.contributor.authorEl-Khoueiry, Anthony
dc.contributor.authorFeng, Mary
dc.contributor.authorKatz, Matthew H G
dc.contributor.authorPrimrose, John
dc.contributor.authorSoares, Heloisa P
dc.contributor.authorValle, Juan
dc.contributor.authorMaithel, Shishir K
dc.date.accessioned2019-08-28T19:49:04Z
dc.date.available2019-08-28T19:49:04Z
dc.date.issued2019-04-20
dc.identifier.citationDOI: 10.1200/JCO.18.02178 Journal of Clinical Oncology 37, no. 12 (April 20, 2019) 1015-1027.en_US
dc.identifier.issn0732-183X
dc.identifier.pmid30856044
dc.identifier.doi10.1200/JCO.18.02178
dc.identifier.urihttp://hdl.handle.net/10150/634019
dc.description.abstractPURPOSE: To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer. METHODS: ASCO convened an Expert Panel to conduct a systematic review of the literature on adjuvant therapy for resected biliary tract cancer and provide recommended care options for this patient population. RESULTS: Three phase III randomized controlled trials, one phase II trial, and 16 retrospective studies met the inclusion criteria. RECOMMENDATIONS: Based on evidence from a phase III randomized controlled trial, patients with resected biliary tract cancer should be offered adjuvant capecitabine chemotherapy for a duration of 6 months. The dosing used in this trial is described in the qualifying statements, while it should be noted that the dose of capecitabine may also be determined by institutional and regional practices. Patients with extrahepatic cholangiocarcinoma or gallbladder cancer and a microscopically positive surgical resection margin (R1 resection) may be offered chemoradiation therapy. A shared decision-making approach is recommended, considering the risk of harm and potential for benefit associated with radiation therapy for patients with extrahepatic cholangiocarcinoma or gallbladder cancer.en_US
dc.language.isoenen_US
dc.publisherAMER SOC CLINICAL ONCOLOGYen_US
dc.rights© 2019 American Society of Clinical Oncology. All rights reserved.en_US
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/
dc.titleAdjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guidelineen_US
dc.typeArticleen_US
dc.identifier.eissn1527-7755
dc.contributor.departmentUniv Arizona, Ctr Cancen_US
dc.identifier.journalJOURNAL OF CLINICAL ONCOLOGYen_US
dc.description.note6 month embargo; published online March 11, 2019en_US
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en_US
dc.eprint.versionFinal published versionen_US
dc.source.journaltitleJournal of clinical oncology : official journal of the American Society of Clinical Oncology


Files in this item

Thumbnail
Name:
jco.18.02178(1).pdf
Size:
607.7Kb
Format:
PDF
Description:
Final Published Version

This item appears in the following Collection(s)

Show simple item record